These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9331515)

  • 21. IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
    Ondo W
    Expert Opin Pharmacother; 2014 Oct; 15(14):2081-5. PubMed ID: 25146967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
    LeWitt PA
    Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection.
    Sagar KA; Smyth MR
    Analyst; 2000 Mar; 125(3):439-45. PubMed ID: 10829343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG; Tanner CM; Gilley DW; Klawans HL
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
    LeWitt PA
    Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA
    Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Motor fluctuations in levodopa treatment: clinical pharmacology.
    Stocchi F; Bonamartini A; Vacca L; Ruggieri S
    Eur Neurol; 1996; 36 Suppl 1():38-42. PubMed ID: 8791020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
    Karstaedt PJ; Pincus JH; Coughlin SS
    Arch Neurol; 1991 Apr; 48(4):402-5. PubMed ID: 2012514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.